Trials / Unknown
UnknownNCT04803851
Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer
Anlotinib Plus Anti-PD-1 Antibody AK105 as Third or More-line Therapy for Advanced Pancreatic Cancer: a Prospective, Single-arm, Open-label, Pilot Study
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 29 (estimated)
- Sponsor
- Peking Union Medical College Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study was designed to explore the clinical efficacy of Anlotinib combined with Anti-PD-1 antibody AK105 in the treatment of third- and above -line advanced pancreatic cancer patients, in order to find a better therapy strategy for pancreatic cancer patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anlotinib plus AK105 | Anlotinib： a multi-kinase inhibitor AK105： an anti-PD-1 antibody |
Timeline
- Start date
- 2021-05-12
- Primary completion
- 2024-02-28
- Completion
- 2024-06-29
- First posted
- 2021-03-18
- Last updated
- 2023-06-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04803851. Inclusion in this directory is not an endorsement.